Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Helperby Therapeutics
Helperby Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Research & Development
How can we save medicine from superbug disaster?
Two leading research teams to collaborate on new fast track antibiotic therapies, with an aim to bring new sophisticated combination therapies to market in a much-reduced timescale
Ingredients
Two of the world’s leading research teams to collaborate on new fast track antibiotic therapies
Aiming to bring new sophisticated combination therapies to market in a much reduced timescale
Regulatory
Treatments to solve global antibiotic crisis may reach the market in 2020
Helperby Therapeutics has developed the first sustainable solution to combat all three deadly critical priority pathogens named by World Health Organisation (WHO)<sup>1</sup>
Research & Development
Helperby Therapeutics and Cadila sign antibiotic drug resistance agreement
Cadila will take a new Helperby compound through Phase III trials, approvals and into commercialisation
Subscribe now